| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Limosilactobacillus reuteri DSM 17938 and PTA 6475 as adjunct in Helicobacter pylori therapy: Systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ruggiero Francavilla, Andrea Iannone, Fernanda Cristofori, Alessia Cafforio, Vanessa N Dargenio, Giovanni La Grasta, Viviana F Brindicci, Stefania P Castellaneta and Michele Barone |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ruggiero Francavilla, Full Professor, MD, PhD, Interdisciplinary Department of Medicine, Pediatric Section, Children’s Hospital ‘Giovanni XXIII’, University of Bari “Aldo Moro”, Via Giovanni Amendola, 207, Bari 70126, Puglia, Italy. ruggiero.francavilla@uniba.it |
| Key Words |
Helicobacter pylori; Limosilactobacillus reuteri; DSM 17938; PTA 6475; Probiotics; Antibiotic-associated side effects; Meta-analysis |
| Core Tip |
Helicobacter pylori (H. pylori) eradication therapy often causes multiple gastrointestinal side effects, limiting adherence. Probiotics, particularly Limosilactobacillus reuteri (L. reuteri), have been suggested as adjuncts to improve tolerability during standard eradication regimens. Our meta-analysis showed L. reuteri supplementation significantly reduced diarrhea, nausea, and dysgeusia during eradication therapy, though without enhancing eradication rates. Benefits were consistent and clinically meaningful across randomized trials. Precision probiotics, such as L. reuteri DSM 17938, may improve patient comfort, adherence, and treatment continuity by reducing side effects, representing a promising supportive strategy in H. pylori management. |
| Publish Date |
2026-09-01 06:22 |
| Citation |
Francavilla R, Iannone A, Cristofori F, Cafforio A, Dargenio VN, La Grasta G, Brindicci VF, Castellaneta SP, Barone M. Limosilactobacillus reuteri DSM 17938 and PTA 6475 as adjunct in Helicobacter pylori therapy: Systematic review and meta-analysis. World J Gastroenterol 2026; 32(37): 119222
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i37/119222.htm |
| DOI |
https://doi.org/10.3748/wjg.119222 |
